Mastercard Inc (MA)vsPfizer Inc (PFE)
MA
Mastercard Inc
$495.48
-1.09%
FINANCIAL SERVICES · Cap: $442.62B
PFE
Pfizer Inc
$25.68
-1.40%
HEALTHCARE · Cap: $150.92B
Smart Verdict
WallStSmart Research — data-driven comparison
Pfizer Inc generates 87% more annual revenue ($63.32B vs $33.94B). MA leads profitability with a 45.9% profit margin vs 11.8%. MA appears more attractively valued with a PEG of 1.57. MA earns a higher WallStSmart Score of 70/100 (B).
MA
Strong Buy70
out of 100
Grade: B
PFE
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for MA.
Margin of Safety
+29.4%
Fair Value
$37.48
Current Price
$25.68
$11.80 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 232 in profit
Keeps 46 of every $100 in revenue as profit
Strong operational efficiency at 60.8%
Safe zone — low bankruptcy risk
15.8% revenue growth
Strong operational efficiency at 31.6%
Large-cap with strong market position
Reasonable price relative to book value
Generating 2.2B in free cash flow
Areas to Watch
Expensive relative to growth rate
Moderate valuation
Trading at 57.3x book value
Elevated debt levels
Weak financial health signals
Expensive relative to growth rate
Earnings declined 10.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : MA
The strongest argument for MA centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 45.9% and operating margin at 60.8%. Revenue growth of 15.8% demonstrates continued momentum.
Bull Case : PFE
The strongest argument for PFE centers on Operating Margin, Market Cap, Price/Book.
Bear Case : MA
The primary concerns for MA are PEG Ratio, P/E Ratio, Price/Book. Debt-to-equity of 2.45 is elevated, increasing financial risk.
Bear Case : PFE
The primary concerns for PFE are Piotroski F-Score, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
MA profiles as a growth stock while PFE is a value play — different risk/reward profiles.
MA carries more volatility with a beta of 0.76 — expect wider price swings.
MA is growing revenue faster at 15.8% — sustainability is the question.
MA generates stronger free cash flow (2.8B), providing more financial flexibility.
Bottom Line
MA scores higher overall (70/100 vs 55/100), backed by strong 45.9% margins and 15.8% revenue growth. PFE offers better value entry with a 29.4% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Mastercard Inc
FINANCIAL SERVICES · CREDIT SERVICES · USA
Mastercard Incorporated is an American multinational financial services corporation headquartered in the Mastercard International Global Headquarters in Purchase, New York. The Global Operations Headquarters is located in O'Fallon, Missouri, a municipality of St. Charles County, Missouri. Throughout the world, its principal business is to process payments between the banks of merchants and the card-issuing banks or credit unions of the purchasers who use the Mastercard brand debit, credit and prepaid cards to make purchases. Mastercard Worldwide has been a publicly traded company since 2006.
Visit Website →Pfizer Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.
Visit Website →Compare with Other CREDIT SERVICES Stocks
Want to dig deeper into these stocks?